Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

5(83.3%)

Phase 4

1(16.7%)

6Total

N/A(5)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02536365Not ApplicableCompleted

Sensory Integration Therapy in Autism: Mechanisms and Effectiveness

Role: collaborator

NCT05105763Not ApplicableUnknown

Biofeedback Gait Retraining for Stiff Knee Gait Correction

Role: collaborator

NCT05011201Not ApplicableUnknown

Dual Joint Visual Feedback Gait Retraining in Pediatric Hemiplegic Cerebral Palsy

Role: collaborator

NCT03730870Not ApplicableTerminated

Pharmacogenomics for Improving Pediatric ADHD Treatment

Role: collaborator

NCT01156051Phase 4Terminated

Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

Role: lead

NCT00291317Not ApplicableCompleted

The Effect of FES on Children With Spinal Cord Injury

Role: lead

All 6 trials loaded